{
    "eid": "2-s2.0-85132207470",
    "title": "A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222",
    "cover-date": "2022-06-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "anti-SARS-CoV-2 IgG",
        "AZD1222",
        "BNT162b2 vaccine",
        "booster dose",
        "ChAdOx1 nCoV-19 vaccine",
        "heterologous prime-boost COVID-19 vaccination",
        "neutralizing antibody titer",
        "SARS-CoV-2 omicron variant",
        "SARS-CoV-2 vaccine"
    ],
    "authors": [
        "Rapisa Nantanee",
        "Watsamon Jantarabenjakul",
        "Peera Jaru-Ampornpan",
        "Pimpayao Sodsai",
        "Orawan Himananto",
        "Jitthiwa Athipunjapong",
        "Jiratchaya Sophonphan",
        "Sira Nanthapisal",
        "Nattiya Hirankarn",
        "Thanyawee Puthanakit"
    ],
    "citedby-count": 1,
    "ref-count": 40,
    "ref-list": [
        "Predictions of the SARS-CoV-2 Omicron Variant (B.1.1.529) Spike Protein Receptor-Binding Domain Structure and Neutralizing Antibody Interactions",
        "Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization",
        "Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum",
        "Protection against the Omicron Variant from Previous SARS-CoV-2 Infection",
        "Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression",
        "Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged \u2265 65 Years\u2014United States, August 13, 2021\u2013November 19, 2021",
        "Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance\u2014VISION Network, 10 States, August 2021\u2013January 2022",
        "Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial",
        "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial",
        "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",
        "Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine",
        "The Advisory Committee on Immunization Practices\u2019 Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines\u2014United States, 2021",
        "Immune response to SARS-CoV-2 after a booster of mRNA-1273: An open-label phase 2 trial",
        "The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series",
        "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection",
        "Testing fractional doses of COVID-19 vaccines",
        "Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination",
        "A serological assay to detect SARS-CoV-2 seroconversion in humans",
        "A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction",
        "COVID-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant",
        "Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults\u2014United States, September 22, 2021\u2013February 6, 2022",
        "Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine",
        "The T cell immune response against SARS-CoV-2",
        "T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals",
        "SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron",
        "Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2",
        "Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in na\u00efve hamsters compared to ancestral vaccine",
        "Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variants",
        "Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice",
        "mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60011947",
            "affilname": "Thailand National Center for Genetic Engineering and Biotechnology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011947",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60031780",
            "affilname": "Thai Red Cross Agency",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031780",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60013939",
            "affilname": "Faculty of Medicine, Thammasat University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013939",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Chulalongkorn University",
        "National Vaccine Institute",
        "Faculty of Medicine, Chulalongkorn University"
    ]
}